ALK-positive anaplastic large cell lymphoma

This page describes systemic ALCL, which can involve lymph nodes and other organs. It is distinct from primary cutaneous ALCL and breast implant-associated ALCL, whose assessment and treatment differ.

The abnormal cells express CD30 and an activated ALK protein, usually produced by a gene fusion. ALK-positive systemic ALCL is more common in children and younger adults than the ALK-negative form. A tissue biopsy and laboratory markers establish the distinction.

An acquired gene rearrangement, most often involving ALK and NPM1, creates a protein that drives cell growth. It is generally a change in the lymphoma cells rather than an inherited alteration.

The reason the rearrangement occurs is usually unknown. The lymphoma cannot be caught from someone else, and the presence of ALK does not make it the same disease as an ALK-positive lung cancer.

Symptoms may include enlarged lymph nodes, fever, drenching night sweats, weight loss and involvement of skin, bone or other organs. Some people have advanced-stage disease at diagnosis but still respond well to treatment.

Stage, age, general condition and the response to therapy influence risk. The generally more favorable behavior of ALK-positive disease is a group observation, not a guarantee for an individual patient.

Treatment follows age-appropriate lymphoma protocols. Adults commonly receive brentuximab vedotin with a chemotherapy combination; pediatric approaches differ and may incorporate targeted treatment in specific settings.

A transplant is not routinely required in first remission for lower-risk ALK-positive disease. Studies supporting autologous consolidation in other peripheral T-cell lymphomas cannot simply be applied to everyone with ALK-positive ALCL.

Relapsed or refractory disease may be treated with brentuximab vedotin, ALK-directed medicines, chemotherapy or clinical trials. Autologous or allogeneic transplantation may be appropriate for selected patients depending on response and previous treatment. Pediatric and adult transplant decisions are not identical.

Treatment can include repeated imaging and clinic visits as well as medicines given over several cycles. Nausea, low blood counts, fatigue or nerve symptoms may need supportive care, depending on the drugs used.

Children and younger adults may need support with school, work, fertility and later health effects. If the lymphoma returns, a new treatment discussion should distinguish the available targeted medicines from the risks and purpose of transplantation.

Most patients do not begin treatment by needing a registry donor. Autologous rescue uses the patient’s own stem cells; only an allogeneic transplant requires another person’s graft.

If allogeneic transplantation is chosen, relatives and unrelated registry donors are among the options, with alternative grafts assessed where appropriate. Registration supports patients who need donated cells across many diseases, including selected difficult-to-treat ALCL.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?